Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.61 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28384304 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL22121638 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL29385011 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL768306 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL7478832 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL1788911 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL10885201 | 1.00 | HRH3 (0.62) | HRH3GNAI3GNAO1GNAI1BCHE | |
| Hydrochloric Acid SCHEMBL4249145 | 0.97 | GNAO1 (0.65) | HRH3GNAI3GNAO1GNAI1BCHE | |
| SCHEMBL251669 | 0.97 | — | — | |
| SCHEMBL1564984 | 0.95 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | HRH3 4103/4885GNAI3 1630/4885GNAO1 2416/4885 |
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | HRH3 4539/4885GNAI3 1659/4885GNAO1 3086/4885 |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | HRH3 4103/4885GNAI3 1630/4885GNAO1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.